Disclosed herein are thieno[3,2-b]pyridine compounds of general formula (I) where the substituents are as defined herein, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are protein tyrosine kinase inhibitors and are intended for use for the treatment of ophthalmic diseases such as chorodial angiogenesis, diabetic retinopathy, age-related macular degeneration or retinal edema. Specific examples of the compounds of formula I include 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((4-(2-(2-(2-methoxyethoxy)ethoxy)acetyl)piperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea and (S)-1-cyclopropyl-3-(4-(2-(5-((4-(2,3-dihydroxypropanoyl)piperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)urea.
